Original Research Article
Galantamine Prolonged-Release Formulation in the Treatment of Mild to Moderate Alzheimer’s DiseaseBrodaty H.a · Corey-Bloom J.b · Potocnik F.C.V.c · Truyen L.d · Gold M.d · Damaraju C.R.V.d
aUniversity of New South Wales, Sydney, Australia; bUniversity of California, San Diego, Calif., USA; cStikland Hospital, Bellville, South Africa; dJohnson & Johnson Pharmaceutical Research and Development, Titusville, N.J., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
The primary objective of this study was to evaluate the efficacy and tolerability of a flexible dosing regimen (16 or 24 mg/day) of galantamine prolonged-release capsule (PRC) compared with placebo in subjects with mild to moderate Alzheimer’s disease (AD). This phase III, double-blind, placebo- and active-controlled, parallel-group trial randomized 971 patients to treatment for 6 months. Efficacy endpoints included change in the 11-item cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-cog/11), Clinician’s Interview-Based Impression of Change plus caregiver input (CIBIC-plus), Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL), and Neuropsychiatric Inventory (NPI) scores. Galantamine was associated with significant improvements in the ADAS-cog/11 score but not in the CIBIC-plus or NPI scores. Galantamine PRC was associated with significant improvement in ADCS-ADL scores. Galantamine PRC had similar tolerability and safety profiles compared with twice-daily galantamine, and when administered as a once-daily flexible dosing regimen of 16 or 24 mg/day, was demonstrated to be as safe and effective for the treatment of mild to moderate AD.
© 2005 S. Karger AG, Basel
Alzheimer’s Disease International: Global impact of dementia. Alzheimer Dis Int, 2002; available at: http://www.alz.co.uk/global/.
- Francis PT, Palmer AM, Snape M, Wilcock GK: The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry 1999;66:137–147.
- Samochocki M, Hoffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C, Radina M, Zerlin M, Ullmer C, Pereira EF, Lubbert H, Albuquerque EX, Maelicke A: Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 2003;305:1024–1036.
Geerts H, Finkel L, Carr R, Spiros A: Nicotinic receptor modulation: advantages for successful Alzheimer’s disease therapy. J Neural Trans 2002;62(suppl):203–216.
- Doggrell SA, Evans S: Treatment of dementia with neurotransmission modulation. Expert Opin Investig Drugs 2003;12:1633–1654.
- Bonner LT, Peskind ER: Pharmacologic treatments of dementia. Med Clin North Am 2002;86:657–674.
- Trinh NH, Hoblyn J, Mohanty S, Yaffe K: Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003;289:210–216.
Olin J, Schneider L: Galantamine for Alzheimer’s disease. Cochrane Database Syst Rev 2001;4:CD001747.
- Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C: A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000;54:2269–2276.
- Raskind MA, Peskind ER, Wessel T, Yuan W: Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000;54:2261–2268.
- Wilcock GK, Lilienfeld S, Gaens E: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000;321:1445–1449.
- Wilkinson D, Murray J: Galantamine: A randomized, double-blind, dose comparison in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 2001;16:852–857.
- Migliaccio-Walle K, Getsios D, Caro JJ, Ishak KJ, O’Brien JA, Papadopoulos G: Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer’s disease in the United States. Clin Ther 2003;25:1806–1825.
- Brookmeyer R, Gray S, Kawas C: Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998;88:1337–1342.
- Jonsson L: Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer’s disease. Pharmacoeconomics 2003;21:1025–1037.
- Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984;141:1356–1364.
- Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH: Validity and reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(suppl 2):S22–S32.
- Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S: An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(suppl 2):S33–S39.
- Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308–2314.
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologies Evaluation and Research: Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; April 1996.
- Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D: Effects of a flexible galantamine dose in Alzheimer’s disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001;71:589–595.
- Boothby H, Mann AH, Barker A: Factors determining interrater agreement with rating global change in dementia: the CIBIC-plus. Int J Geriatr Psychiatry 1995;10:1037–1045.
- Connell CM, Janevic MR, Gallant MP: The costs of caring: impact of dementia on family caregivers. J Geriatr Psychiatry Neurol 2001;14:179–187.
- Veitch C, Hollins J, Worley P, Mitchell G: General practice research. Problems and solutions in participant recruitment and retention. Aust Fam Physician 2001;30:399–406.
- Ranelli PL, Aversa SL: Medication-related stressors among family caregivers. Am J Hosp Pharm 1994;51:75–79.
- Claxton AJ, Cramer J, Pierce C: A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296–1310.
- Dezii CM, Kawabata H, Tran M: Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J 2002;95:68–71.
- Boucher L, Renvall MJ, Jackson JE: Cognitively impaired spouses as primary caregivers for demented elderly people. J Am Geriatr Soc 1996;44:828–831.
- Yamada H, Sugiyama T, Ashida T, Ohwaki H, Fujii J: Medication management skill and regimen compliance are deteriorated in the elderly even without obvious dementia. Yakugaku Zasshi 2001;121:187–190.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.